Articles By Rob Wright, Chief Editor

Back to the office
When Will Biopharma Be Back In The Office?
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.  Continue Reading..
  • 35-Year Biopharma R&D Vet Takes On His Second Startup

    Norbert Bischofberger, Ph.D., had a good job at Gilead where he had worked for nearly two decades. Then, out of the blue, he found out he was being considered for a CEO position at a small startup called Kronos Bio.

  • Can Employers Deliver On What Today’s Employees Seek?

    The big question on the minds of all companies is: Is it possible to achieve what today’s employees seek in a 100% virtual environment?

  • What’s It Like Being A First-Time Biopharma CEO?

    In this edited transcript of our June 2021 executive virtual roundtable, three first-time CEOs tell us their tales of the good, the bad, and the ugly related to being CEO.

  • When It’s Time

    When pondering if she wanted to spend the next 10 to 15 years continuing to climb that academic ladder or do something that would be impactful for patients, Laura Niklason, M.D., Ph.D., opted for the latter.

  • From Professor To Regenerative Medicine Company CEO

    Though she cofounded the company in 2004 and played an active role throughout its growth, until November 2020, Laura Niklason, M.D., Ph.D., had never held a c-level title within it.

  • IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public

    Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies. As 2020 forever changed how IPOs are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.

  • Mental Wellness — The Next Big Thing

    Recent events of female athletes expressing the need to focus on their mental health seems to point toward mental wellness being one of the next big things, along with women leaders being willing to "rewrite the rules."

  • Is Government-Enabled IP Theft Ever A Good Thing?

    I believe waiving IP protections on COVID-19 vaccines (developed by three U.S. companies in record time) will not have any appreciable impact on fixing the global health crisis in the short term.

  • How A First-Time CEO Transformed Retrophin Into Travere Therapeutics

    Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Martin Shkreli?). But he took the job in January 2019 and now has guided the $1.5 billion biopharma as it has increased sales, implemented a new diverse and inclusive culture, advanced its pipeline, and adopted a new name (Travere).

Rob Wright author page

Rob Wright

Rob Wright is the chief editor of Life Science Leader magazine. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL